Association between polycystic ovary syndrome and metabolic syndrome
- PMID: 25245380
- DOI: 10.2174/0929867321666140915141030
Association between polycystic ovary syndrome and metabolic syndrome
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder affecting women in reproductive age. Although the etiology of PCOS remains unclear, it is believed to result from genetic, environmental and behavioral interactions. Women with PCOS have higher lifetime risk for cardiovascular disease (CVR) than healthy women at the same age and tend to display insulin resistance (IR). IR has traditionally been defined as a decreased ability of insulin to mediate the metabolic actions on glucose uptake, glucose production, and/or lipolysis. This results in a requirement for increased amounts of insulin to achieve a given metabolic action. Metabolic syndrome (MS) includes hyperinsulinemia, dyslipidemia, increased CVR and hyperleptinemia and metabolic disorders such as hypertension, IR, gestational diabetes, type 2 diabetes mellitus, systemic inflammation and endothelial dysfunction. The prevalence of MS in women is around 50 %. In addition, it has been recently suggested that women with MS show increased circulating androgens. The present review discusses the main alterations and features of PCOS and MS and the most important treatments.
Similar articles
-
Metformin in polycystic ovary syndrome.Ann N Y Acad Sci. 2010 Sep;1205:192-8. doi: 10.1111/j.1749-6632.2010.05679.x. Ann N Y Acad Sci. 2010. PMID: 20840272 Review.
-
Insulin and the polycystic ovary syndrome.Diabetes Res Clin Pract. 2017 Aug;130:163-170. doi: 10.1016/j.diabres.2017.06.011. Epub 2017 Jun 12. Diabetes Res Clin Pract. 2017. PMID: 28646699 Review.
-
Polycystic ovary syndrome, adipose tissue and metabolic syndrome.Arch Gynecol Obstet. 2017 Sep;296(3):405-419. doi: 10.1007/s00404-017-4429-2. Epub 2017 Jun 22. Arch Gynecol Obstet. 2017. PMID: 28643028 Review.
-
The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.Gynecol Endocrinol. 2018 Feb;34(2):87-91. doi: 10.1080/09513590.2017.1381681. Epub 2017 Sep 23. Gynecol Endocrinol. 2018. PMID: 28944709 Review.
-
Adiposity and metabolic dysfunction in polycystic ovary syndrome.Horm Mol Biol Clin Investig. 2015 Feb;21(2):107-16. doi: 10.1515/hmbci-2015-0008. Horm Mol Biol Clin Investig. 2015. PMID: 25781555 Review.
Cited by
-
Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis.Int J Endocrinol. 2015;2015:294278. doi: 10.1155/2015/294278. Epub 2015 Sep 27. Int J Endocrinol. 2015. PMID: 26491440 Free PMC article. Review.
-
Modulation of the Inflammatory Response in Polycystic Ovary Syndrome (PCOS)-Searching for Epigenetic Factors.Int J Mol Sci. 2022 Nov 24;23(23):14663. doi: 10.3390/ijms232314663. Int J Mol Sci. 2022. PMID: 36498989 Free PMC article. Review.
-
Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome.J Int Med Res. 2016 Aug;44(4):796-805. doi: 10.1177/0300060516645421. Epub 2016 May 25. J Int Med Res. 2016. PMID: 27225862 Free PMC article.
-
Alterations of Sphingolipid Metabolism in Different Types of Polycystic Ovary Syndrome.Sci Rep. 2019 Mar 1;9(1):3204. doi: 10.1038/s41598-019-38944-6. Sci Rep. 2019. PMID: 30824725 Free PMC article.
-
Abnormal Activation of Tryptophan-Kynurenine Pathway in Women With Polycystic Ovary Syndrome.Front Endocrinol (Lausanne). 2022 Jun 1;13:877807. doi: 10.3389/fendo.2022.877807. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35721725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical